Featured Press Releases
BIO Statement on the Section 232 Pharmaceutical…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on Section 232 Pharmaceutical Proclamation.“A thriving American biotechnology ecosystem is essential to…
BIO Statement on Passage of Legislation…
WASHINGTON, D.C. - Brad Zakes, senior vice president for emerging companies and economic affairs at the Biotechnology Innovation Organization (BIO), released the following statement on passage of legislation reauthorizing the SBIR/STTR program:"The…
Announcing Investor Connect Plus: A LaunchBio x…
Accelerating Growth Through ConnectionsLaunchBio and the Biotechnology Innovation Organization (BIO) today announced the launch of Investor Connect Plus, an exclusive, BIO member-only investor access program designed for established, capital-ready…
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved